Phase II study of lonidamine in metastatic breast cancer.

Thirty patients with previously treated metastatic breast cancer were entered in a phase II study with oral lonidamine. Twenty-eight patients are evaluable for toxicity and 25 for response. A partial remission was obtained in four patients (16%) and disease stability in 11 (44%): 10 patients progres...

Descripción completa

Detalles Bibliográficos
Autores principales: Pronzato, P., Amoroso, D., Bertelli, G., Conte, P. F., Cusimano, M. P., Ciottoli, G. B., Gulisano, M., Lionetto, R., Rosso, R.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1989
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247009/
https://www.ncbi.nlm.nih.gov/pubmed/2930690
_version_ 1782150889679618048
author Pronzato, P.
Amoroso, D.
Bertelli, G.
Conte, P. F.
Cusimano, M. P.
Ciottoli, G. B.
Gulisano, M.
Lionetto, R.
Rosso, R.
author_facet Pronzato, P.
Amoroso, D.
Bertelli, G.
Conte, P. F.
Cusimano, M. P.
Ciottoli, G. B.
Gulisano, M.
Lionetto, R.
Rosso, R.
author_sort Pronzato, P.
collection PubMed
description Thirty patients with previously treated metastatic breast cancer were entered in a phase II study with oral lonidamine. Twenty-eight patients are evaluable for toxicity and 25 for response. A partial remission was obtained in four patients (16%) and disease stability in 11 (44%): 10 patients progressed (40%). Toxicity was acceptable, consisting mainly of myalgias (39% of patients) and asthenia (21.4%). No myelotoxicity was observed. The drug is active in previously treated metastatic breast cancer and, because of its peculiar pattern of action and toxicity, deserves to be evaluated in combination with cytotoxic chemotherapy.
format Text
id pubmed-2247009
institution National Center for Biotechnology Information
language English
publishDate 1989
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-22470092009-09-10 Phase II study of lonidamine in metastatic breast cancer. Pronzato, P. Amoroso, D. Bertelli, G. Conte, P. F. Cusimano, M. P. Ciottoli, G. B. Gulisano, M. Lionetto, R. Rosso, R. Br J Cancer Research Article Thirty patients with previously treated metastatic breast cancer were entered in a phase II study with oral lonidamine. Twenty-eight patients are evaluable for toxicity and 25 for response. A partial remission was obtained in four patients (16%) and disease stability in 11 (44%): 10 patients progressed (40%). Toxicity was acceptable, consisting mainly of myalgias (39% of patients) and asthenia (21.4%). No myelotoxicity was observed. The drug is active in previously treated metastatic breast cancer and, because of its peculiar pattern of action and toxicity, deserves to be evaluated in combination with cytotoxic chemotherapy. Nature Publishing Group 1989-02 /pmc/articles/PMC2247009/ /pubmed/2930690 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Pronzato, P.
Amoroso, D.
Bertelli, G.
Conte, P. F.
Cusimano, M. P.
Ciottoli, G. B.
Gulisano, M.
Lionetto, R.
Rosso, R.
Phase II study of lonidamine in metastatic breast cancer.
title Phase II study of lonidamine in metastatic breast cancer.
title_full Phase II study of lonidamine in metastatic breast cancer.
title_fullStr Phase II study of lonidamine in metastatic breast cancer.
title_full_unstemmed Phase II study of lonidamine in metastatic breast cancer.
title_short Phase II study of lonidamine in metastatic breast cancer.
title_sort phase ii study of lonidamine in metastatic breast cancer.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247009/
https://www.ncbi.nlm.nih.gov/pubmed/2930690
work_keys_str_mv AT pronzatop phaseiistudyoflonidamineinmetastaticbreastcancer
AT amorosod phaseiistudyoflonidamineinmetastaticbreastcancer
AT bertellig phaseiistudyoflonidamineinmetastaticbreastcancer
AT contepf phaseiistudyoflonidamineinmetastaticbreastcancer
AT cusimanomp phaseiistudyoflonidamineinmetastaticbreastcancer
AT ciottoligb phaseiistudyoflonidamineinmetastaticbreastcancer
AT gulisanom phaseiistudyoflonidamineinmetastaticbreastcancer
AT lionettor phaseiistudyoflonidamineinmetastaticbreastcancer
AT rossor phaseiistudyoflonidamineinmetastaticbreastcancer

Ejemplares similares